The stock price of SAB Biotherapeutics Inc (NASDAQ: SABS) has jumped by 8.77 compared to previous close of 1.71. Despite this, the company has seen a fall of -4.12% in its stock price over the last five trading days. globenewswire.com reported 2025-05-09 that MIAMI, May 09, 2025 (GLOBE NEWSWIRE) — SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced financial results for the quarter ending March 31, 2025, and reported on recent developments. Samuel J. Reich, Chairman and CEO of SAB BIO, stated, “We have made strong progress this quarter on our corporate strategy and mission to deliver a transformational therapy that can halt or delay the progression of type 1 diabetes.
Is It Worth Investing in SAB Biotherapeutics Inc (NASDAQ: SABS) Right Now?
SABS has 36-month beta value of 0.49. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SABS is 7.49M, and currently, short sellers hold a 1.33% ratio of that float. The average trading volume of SABS on May 23, 2025 was 43.94K shares.
SABS’s Market Performance
SABS’s stock has seen a -4.12% decrease for the week, with a 35.77% rise in the past month and a 2.20% gain in the past quarter. The volatility ratio for the week is 6.82%, and the volatility levels for the past 30 days are at 6.08% for SAB Biotherapeutics Inc The simple moving average for the past 20 days is 4.86% for SABS’s stock, with a -27.20% simple moving average for the past 200 days.
Analysts’ Opinion of SABS
Many brokerage firms have already submitted their reports for SABS stocks, with H.C. Wainwright repeating the rating for SABS by listing it as a “Buy.” The predicted price for SABS in the upcoming period, according to H.C. Wainwright is $10 based on the research report published on May 14, 2025 of the current year 2025.
Craig Hallum, on the other hand, stated in their research note that they expect to see SABS reach a price target of $11. The rating they have provided for SABS stocks is “Buy” according to the report published on October 09th, 2024.
Oppenheimer gave a rating of “Outperform” to SABS, setting the target price at $12 in the report published on August 28th of the previous year.
SABS Trading at 19.42% from the 50-Day Moving Average
After a stumble in the market that brought SABS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.87% of loss for the given period.
Volatility was left at 6.08%, however, over the last 30 days, the volatility rate increased by 6.82%, as shares surge +24.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +16.25% upper at present.
During the last 5 trading sessions, SABS fell by -4.12%, which changed the moving average for the period of 200-days by -28.46% in comparison to the 20-day moving average, which settled at $1.7737. In addition, SAB Biotherapeutics Inc saw -50.98% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for SABS
Current profitability levels for the company are sitting at:
- -111.93 for the present operating margin
- 2.75 for the gross margin
The net margin for SAB Biotherapeutics Inc stands at -90.72. The total capital return value is set at -1.49. Equity return is now at value -92.35, with -62.61 for asset returns.
Based on SAB Biotherapeutics Inc (SABS), the company’s capital structure generated 0.24 points at debt to capital in total, while cash flow to debt ratio is standing at -4.63. The debt to equity ratio resting at 0.32. The interest coverage ratio of the stock is -245.22.
Currently, EBITDA for the company is -28.99 million with net debt to EBITDA at -0.03. When we switch over and look at the enterprise to sales, we see a ratio of 48.77. The receivables turnover for the company is 17.67for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.69.
Conclusion
To put it simply, SAB Biotherapeutics Inc (SABS) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
